35 are preclinical, and one is on a human trial, and so it was very limited in human research, so we got a lot of rats and dogs that were utilized for these studies
Although early research shows promise, it remains largely experimental, and long-term safety data is still limited
Protocol 3: metabolic health optimization Goal: Reduce liver fat, improve insulin sensitivity, address metabolic syndrome Tirzepatide approach: Standard escalation to 10 mg Produces moderate liver fat reduction Significant HbA1c improvements (if diabetic) Meaningful but not maximal metabolic improvements Retatrutide approach: Escalation to 8-12 mg 86% of patients achieved normal liver fat at 12 mg Superior metabolic marker improvements across all measures Glucagon component directly targets hepatic lipid metabolism If metabolic health is your primary goal rather than the number on the scale, the retatrutide dosage chart offers something tirzepatide fundamentally cannot: direct glucagon-mediated liver fat reduction
Lin ZY, Wu Y, Xu G, Li Z, Li T, Liu
Taddei S, Versari D, Cipriano A, Ghiadoni L, Galetta F, Franzoni F, Magagna A, Virdis A, Salvetti A
